Thursday, October 12, 2017

Mavyret (Glecaprevir and Pibrentasvir) - Combo confirmed as safe and effective for HCV patients with chronic kidney disease

Sustained Response with HCV Combo Drug in CKD
Patients with both diseases had virologic response and no failure

by Molly Walker, Staff Writer, MedPage Today
October 11, 2017
A combination therapy for patients with chronic kidney disease (CKD) and hepatitis C (HCV) was confirmed as safe and effective, according to researchers in New Zealand.

Overall, 102 of 104 patients (98% virologic response rate, 95% CI 95-100) treated with the combination of NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir (Mavyret) for 12 weeks had a sustained virologic response rate, with no patients reporting virologic failure, reported Edward Gane, MD, of Auckland City Hospital, and colleagues.

Preliminary results were first presented at the 2016 American Association for the Study of Liver Diseases (AASLD) annual meeting. Gane's group have now published the full peer-reviewed results of the phase III trial in the New England Journal of Medicine. The combination therapy received FDA approval in August 2017, and is indicated for the treatment of all major genotypes (GT1-6) of chronic HCV.

No comments:

Post a Comment